How Are CDMOs Using AI?

The global CDMO market was valued at around $245 billion in 2024 and is expected to reach close to $490 billion by 2034. The growth is being driven by large pharma companies outsourcing more of their development and manufacturing work, demand for specialised capabilities in biologics and cell and gene therapies, and ongoing pressure to reduce the cost and time of bringing drugs to market. CDMOs that can demonstrate faster turnaround, tighter quality control, and stronger compliance records win more contracts. AI is increasingly how they do it.

The AI applications relevant to CDMOs are not identical to those relevant to drug originators. CDMOs run multiple programmes for multiple clients simultaneously, with strict information barriers between them. They operate under tight timelines and cost constraints. And they bear the compliance burden for the manufacturing and development work they perform, regardless of which client owns the product. These constraints shape which AI investments deliver returns.

Process Development and Formulation

CDMOs carry out formulation development, process optimisation, and scale-up work across many different molecules and delivery forms. A significant proportion of this work involves retrieving and applying knowledge from prior development programmes. Knowing that a particular excipient caused compatibility issues in a prior formulation, or that a specific granulation approach was successful for a molecule with similar properties, is valuable institutional knowledge that typically lives in development reports and lab notebooks rather than in a searchable system.

AI-powered knowledge search changes this. Development scientists can query the organisation's full historical corpus in natural language, retrieving relevant prior work in seconds regardless of how it was originally documented. The impact is measurable: less duplicated experimental work, faster identification of starting points for new programmes, and better use of the organisation's accumulated development experience.

Manufacturing Quality and Process Control

On the manufacturing floor, CDMOs are applying AI to predictive quality control and equipment monitoring. AI systems trained on historical batch data can flag process parameters that have historically preceded batch failures, allowing interventions before a batch is lost. Predictive maintenance models reduce unplanned equipment downtime by anticipating failures before they occur. Early adopters in pharmaceutical manufacturing report 30 to 50 percent reductions in unplanned downtime following deployment of predictive maintenance AI.

Digital twin technology, where a virtual model of a manufacturing process is continuously updated with real-time sensor data, is also being adopted by larger CDMOs. The digital twin allows process engineers to simulate changes before implementing them on the production line, reducing the cost and risk of process optimisation and scale-up.

Documentation and Regulatory Compliance

For CDMOs, the documentation burden is particularly heavy. Every batch must have a complete, auditable record. SOPs must be current, version-controlled, and accessible to manufacturing staff. Deviation investigations must be documented and closed within defined timeframes. And for CDMOs working with US-based clients, 21 CFR Part 11 compliance adds electronic record and signature requirements to every GMP system.

AI-assisted documentation systems address this burden directly. Electronic batch records with automated audit trails eliminate the transcription errors and audit trail gaps that are among the most common sources of regulatory observations. AI document search makes SOPs retrievable during audits without manual folder navigation. And deviation management systems with automated routing and timeline tracking ensure that CAPA closure rates meet regulatory expectations.

Client-Facing Knowledge and Reporting

CDMOs also interact intensively with clients. Development updates, batch reports, analytical results, and regulatory submissions flow between the CDMO and the client throughout every programme. AI systems that can extract structured information from these documents, generate summaries, and flag discrepancies against prior reports reduce the manual effort in client-facing work and reduce the risk of errors in communications that have regulatory implications.

The Data Security Constraint

One constraint is universal across CDMO AI deployments: proprietary client data cannot leave the CDMO's controlled environment. A CDMO processing formulation data, synthesis routes, or clinical batch records for a client cannot send that data to external AI APIs. Any AI system used for GMP documentation, formulation search, or quality analysis must run within the CDMO's own infrastructure. On-premise deployment is not a preference for most CDMOs working with innovative drug originators. It is a contractual and regulatory requirement.

This shapes the vendor landscape significantly. Cloud-first AI tools that depend on sending data to external servers are not viable for the core compliance and IP-sensitive applications. CDMOs evaluating AI vendors need to verify on-premise deployment capability before any other consideration.